Proteintech

PD-L1/CD274

#PE-FcA98062 · western blot · $190

200
Citing papers
8.7k
Combined citations
Supplier page Find this product

Research areas

Cancer Immunotherapy and Biomarkers60Immune cells in cancer35Ferroptosis and cancer prognosis30RNA modifications and cancer19Immunotherapy and Immune Responses18Immune Cell Function and Interaction18Extracellular vesicles in disease18Circular RNAs in diseases15

Papers citing this product

1
Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target
Nature Communications·2022·450 cit.·DOI
2
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Nature Communications·2018·427 cit.·DOI
3
Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer
Cell Death and Disease·2019·342 cit.·DOI
4
PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer
Cell Death and Disease·2020·193 cit.·DOI
5
circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway
Molecular Cancer·2020·179 cit.·DOI
6
A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma
Nature Communications·2023·179 cit.·DOI
7
Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
Journal for ImmunoTherapy of Cancer·2020·171 cit.·DOI
8
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition
PLoS ONE·2017·164 cit.·DOI
9
PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
Journal of Hematology & Oncology·2018·162 cit.·DOI
10
CXCL5 promotes gastric cancer metastasis by inducing epithelial-mesenchymal transition and activating neutrophils
Oncogenesis·2020·153 cit.·DOI

Also available from other vendors

This target has 400 citing papers across all vendors combined

VendorProductPricePapers
ProteintechPD-L1/CD274$116200
ProteintechPD-L1/CD274$140200
ProteintechPD-L1/CD274$158200
ProteintechPD-L1/CD274$195200
ProteintechPD-L1/CD274$210200
ProteintechPD-L1/CD274$250200
ProteintechPD-L1/CD274$267200
ProteintechPD-L1/CD274$267200
Cytek BiosciencesPE Anti-Mouse CD274 (PD-L1, B7-H1) (10F.9G2)—200

Similar products

ProductVendorPricePapers
PD-L1/CD274RabbitProteintech$210200
PD-L1/CD274RabbitProteintech$195200
PD-L1/CD274RabbitProteintech$267200
PD-L1/CD274RabbitProteintech$116200
PD-L1/CD274RabbitProteintech$158200
PD-L1/CD274RabbitProteintech$140200
PD-L1/CD274RabbitProteintech$250200
PD-L1/CD274RabbitProteintech$267200
Anti-PD-L1/CD274 Antibody (Clone#IDC-3)RabbitBoster Biological Technology—3